文献速递乳腺癌

曲妥珠单抗单药一线治疗HER2过表达转移性乳腺癌的疗效与安全性

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer.
PubMed 文献 · J Clin Oncol · 2023-01-01

114例HER2过表达转移性乳腺癌女性随机接受曲妥珠单抗一线单药治疗(4 mg/kg负荷后2 mg/kg每周,或8 mg/kg负荷后4 mg/kg每周)。总客观缓解率26%(95%CI 18.2%~34.4%);IHC 3+者缓解率35%,IHC 2+者无缓解;FISH阳性者缓解率34%,FISH阴性者7%。单药有活性且耐受良好。

要点

  • 曲妥珠单抗单药一线治疗HER2过表达转移性乳腺癌总客观缓解率26%(95%CI 18.2%~34.4%)。
  • IHC 3+者缓解率35%(95%CI 24.4%~44.7%),IHC 2+者无缓解(95%CI 0%~15.5%)。
  • 最常见治疗相关不良事件为寒战25%、乏力23%、发热22%、疼痛18%、恶心14%。

核心结论

  • 曲妥珠单抗单药对IHC 3+过表达或FISH基因扩增的转移性乳腺癌女性一线治疗有活性且耐受良好。

研究设计与样本

  • 114例HER2过表达转移性乳腺癌女性随机接受曲妥珠单抗一线单药治疗,方案为4 mg/kg负荷后2 mg/kg每周或8 mg/kg负荷后4 mg/kg每周。

主要发现

  • 总客观缓解率26%(95%CI 18.2%~34.4%),其中完全缓解7例、部分缓解23例。
  • 111例可评估患者中,IHC 3+者缓解率35%(95%CI 24.4%~44.7%),IHC 2+者无缓解(95%CI 0%~15.5%)。
  • IHC 3+和2+可评估患者的临床获益率分别为48%和7%。
  • 108例可评估患者中,FISH阳性者缓解率34%(95%CI 23.9%~45.7%),FISH阴性者7%(95%CI 0.8%~22.8%)。
  • 30例客观缓解患者中17例(57%)、43例临床获益患者中22例(51%)在12个月或更晚随访时未出现疾病进展。

关键数值与推荐

  • 最常见治疗相关不良事件:寒战25%、乏力23%、发热22%、疼痛18%、恶心14%。
  • 心脏功能障碍发生于2例患者(2%),两例均有心脏病史,停用曲妥珠单抗后无需额外干预。
  • 缓解、生存或不良事件均无明确的剂量-反应关系证据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS: One hundred fourteen women with HER2-overexpressing metastatic breast cancer were randomized to receive first-line treatment with trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly, or a higher 8 mg/kg loading dose, followed by 4 mg/kg weekly. RESULTS: The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses. Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively. The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively. The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively. Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later. The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%). Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab. There was no clear evidence of a dose-response relationship for response, survival, or adverse events. CONCLUSION: Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer. J Clin Oncol. 2023. PMID: 36921335. doi:10.1200/JCO.22.02516

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。